$PRME
Prime Medicine, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
$3.15
▲+0.32%+$0.010
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonatePrime Medicine, Inc. Common Stock
XNAS•Health Care•Biological Products, (No Diagnostic Substances)
Why is PRME up today? It is at $3.15 (+0.32%), and our scanner flagged it 103 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment PRME spikes, and full due diligence on PRME — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $PRME 103 times in the last 30 days. Create a free account to track $PRME, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on PRME from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for PRME today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalystPrime Medicine, Inc.: Q2 FY2026 results, three months to Jun 30, 2026, from an SEC filing. Read it →From the trading subreddits (WallStreetBets, r/stocks and more). Retail chatter, not a signal. Do your own research.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Arch Venture Partners X, Llc Beneficial Owner (10%) | Bought (open market) | +3.03M 1.7% of company | added 20% | 18.49M | $10.0M at $3.30 | Aug 1, 25 |
Arch Venture Partners Xii, Llc Beneficial Owner (10%) | Bought (open market) | +3.03M 1.7% of company | added 20% | 18.49M | $10.0M at $3.30 | Aug 1, 25 |
Nelsen Robert Director | Bought (open market) | +3.03M 1.7% of company | added 20% | 18.50M | $10.0M at $3.30 | Aug 1, 25 |
Gv 2021 Gp, L.L.C. Beneficial Owner (10%) | Bought (open market) | +1.50M 0.8% of company | added 85% | 3.26M | $5.0M at $3.30 | Aug 1, 25 |
Liu David R. Beneficial Owner (10%) | Acquired (grant/award) | +21K 0.01% of company | added 0.1% | 20.24M | $53K at $2.52 | Jun 30, 25 |
Liu David R. Beneficial Owner (10%) | Acquired (grant/award) | +21K 0.01% of company | added 0.1% | 20.22M | $45K at $2.16 | Jun 23, 25 |
Liu David R. Beneficial Owner (10%) | Acquired (grant/award) | +21K 0.01% of company | added 0.1% | 20.20M | $31K at $1.49 | Jun 16, 25 |
Liu David R. Beneficial Owner (10%) | Acquired (grant/award) | +21K 0.01% of company | added 0.1% | 20.18M | $34K at $1.60 | Jun 11, 25 |
Reine Allan Officer | Bought (open market) | +125K 0.07% of company | n/a | 125K | $148K at $1.18 | May 21, 25 |
Lee Ann L. Officer | Bought (open market) | +100K 0.06% of company | n/a | 100K | $113K at $1.13 | May 21, 25 |
Brudnick Richard Officer | Bought (open market) | +20K 0.01% of company | n/a | 20K | $24K at $1.19 | May 20, 25 |
Gottesdiener Keith Michael Officer | Sold (automatic/other) | -227K 0.1% of company | sold 82% | 50K | n/a | Oct 8, 24 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Comparable names in biological products, (no diagnostic substances), closest in size first.
Here is the latest on PRME from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for PRME today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
PRME last traded at $3.15, up 0.32% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Prime Medicine, Inc. Common Stock (PRME) is next expected to report earnings on Friday, November 6, 2026, about 47 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
Yes. PRME currently has a dividend yield of about 102.56% ($3.20 per share per year). Dividend figures can change; this is not investment advice.
The PRME Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged PRME 103 times in the last 30 days.
PRME (Prime Medicine, Inc. Common Stock) trades on XNAS, with a market cap of about $566M in the Biological Products, (No Diagnostic Substances) sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge PRME for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$PRME discussion
Sign in to ask a question or join the discussion.